Chemo-Radiotherapy Boost Treatment Guided by Perfusion MRI on Hypoxic Zones in Head and Neck Cancer

Exclusion Criteria

• •Documented allergy to radiological contrast media or inability to receive contrast media due to concomitant pathology (e.g. renal);
• •inability to receive radiotherapy (e.g. previous radiotherapy in the same region) and/or chemotherapy (inadequate bone marrow and/or liver and/or renal function);
• •incomplete acquisition of MRI images;
• •performance status 2 or more according to Zubrod;
• •Previous invasive neoplasm (except skin cancer), except for neoplasms controlled for at least three years; non-invasive tumors (e.g. carcinoma in situ of the breast) are admitted even if diagnosed and treated in a period less than 3 years prior; patients with simultaneous or bilateral primary tumors are excluded;
• •alcohol or drug abuse;
• •legal incapacity or limited legal capacity;
• •concomitant treatment with investigational drugs or participation in another clinical trial with use of investigational drugs within 30 days prior to screening for the study;
• •documented hypersensitivity to study drugs or any of their excipients;
• •pregnancy and/or breastfeeding.